PLAU and neoplasm: Both uPA and ADAM proteases are recognized as valuable biomarkers for cancer prognosis and a number of selective inhibitors of these proteins (INCB7839, INCB3619) [42], [45], [46] have revealed promising anti-tumor responses in phase I/II trials.